Molecular epidemiological characterization of influenza A（H3N2） virus in Fengxian District， Shanghai， in the surveillance year of 2023
10.19428/j.cnki.sjpm.2025.24278
- VernacularTitle:2023监测年上海市奉贤区甲型H3N2亚型流感病毒分子流行特征分析
- Author:
Hongwei ZHAO
1
;
Lixin TAO
1
;
Xiaohong XIE
1
;
Yi HU
2
;
Xue ZHAO
3
;
Meihua LIU
1
;
Qingyuan ZHANG
1
;
Lijie LU
1
;
Chen’an LIU
1
;
Mei WU
1
Author Information
1. Fengxian District Center for Disease Control and Prevention, Shanghai 201499, China
2. School of Public Health, Fudan University, Shanghai 200032, China
3. Institute for the Control of Pathogenic Organisms, Shanghai Municipal Center for Disease Control and Prevention, Shanghai 200336, China
- Publication Type:Journal Article
- Keywords:
influenza A (H3N2) virus;
hemagglutinin;
neuraminidase;
molecular epidemiological characteristic
- From:
Shanghai Journal of Preventive Medicine
2025;37(1):18-22
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo understand the epidemiological distribution and gene evolutionary variation of influenza A (H3N2) viruses in Fengxian District, Shanghai, in the surveillance year of 2023, and to provide a reference basis for influenza prevention and control. MethodsThe prevalence of influenza virus in Fengxian District in the 2023 influenza surveillance year (April 2023‒March 2024) was analyzed. The hemagglutinin (HA) gene, neuraminidase (NA) gene, and amino acid sequences of 75 strains of H3N2 influenza viruses were compared with the vaccine reference strain for similarity matching and phylogenetic evolutionary analysis, in addition to an analysis of gene characterization and variation. ResultsIn Fengxian District, there was a mixed epidemic of H3N2 and H1N1 in the spring of 2023, with H3N2 being the predominant subtype in the second half of the year, and Victoria B becoming the predominant subtype in the spring of 2024. A total of 75 influenza strains of H3N2 with HA and NA genes were distributed in the 3C.2a1b.2a.2a.2a.3a.1 and B.4 branches, with overall similarity to the reference strain of the 2024 vaccine higher than that of the reference strain of the 2022 and 2023 vaccine. Compared with the 2023 vaccine reference strain, three antigenic sites and one receptor binding site were changed in HA, with three glycosylation sites reduced and two glycosylation sites added; where as in NA seven antigenic sites and the 222nd resistance site changed with two glycosylation sites reduced. ConclusionThe risk of antigenic variation and drug resistance of H3N2 in this region is high, and it is necessary to strengthen the publicity and education on the 2024 influenza vaccine and long-term monitoring of influenza virus prevalence and variation levels.
